Intralipid as treatment for recurrent unexplained abortion?
OBJECTIVE
Safe, effective, and inexpensive alternatives to partner leukocyte immunotherapy are being sought. Psychotherapy may be effective but it is uncertain what constitutes effective treatment and the form of treatment tested in cohort controlled trials is expensive. IVIG also appears effective, but is expensive.


METHODS
A published double blind randomized controlled trial in which Intralipid (Kabi Vitrum, Toronto, Ontario) was used as a control versus trophoblast membrane vesicles was reviewed. A prediction made from this data was then tested using the DBA/2-mated CBA/J mouse model of recurrent spontaneous abortion.


RESULTS
It can be hypothesized from the human clinical trial data that Intralipid even in small doses could be an effective antiabortion treatment. The number of patients in the published study is too small for the required degree of precision. Intralipid was highly effective in preventing abortion in mice, and protection was prolonged. This may be explained by previous data in the literature showing that Intralipid affects the reticuloendothelial system of the recipient.


CONCLUSIONS
The evidence suggests that Intralipid might be an effective treatment for human recurrent miscarriages, and injection into women who may become pregnant has been found ethically acceptable at one university center. Comparison of Intralipid to partner leukocyte immunotherapy or IVIG would be worthwhile. For adequate statistical power, this would require a large, multicenter, prognostically stratified randomized controlled trial and could be accomplished via the Recurrent Miscarriage Immunotherapy Trialists Group network.
Clark
D A
DA
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
D000026:Abortion, Habitual / Q000276:immunology / Q000628:therapy*; D000818:Animals; D004195:Disease Models, Animal; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005327:Fetal Resorption / Q000517:prevention & control; D007155:Immunologic Factors / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D011247:Pregnancy; D011292:Premedication
D005217:Fat Emulsions, Intravenous; D007155:Immunologic Factors